on INVENTIVA (EPA:IVA)
Inventiva at Canaccord Genuity 45th Annual Growth Conference
Inventiva, a Daix-based biopharmaceutical company specializing in the treatment of metabolic steatohepatitis (MASH), announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The event will take place in Boston from August 12 to 14, 2025.
Jason Campagna, President of R&D and Chief Medical Officer, and David Nikodem, Vice President of US Operations, will represent the company during a fireside chat. The program will include a presentation of the latest therapeutic advances, including lanifibranor and the NATiV3 Phase III clinical trial in MASH, as well as a discussion on Inventiva's R&D strategy.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news